GRI Bio (NASDAQ:GRI) Price Target Raised to $13.00

GRI Bio (NASDAQ:GRI) had its price target upped by Ascendiant Capital Markets from $12.00 to $13.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

GRI Bio Stock Performance

GRI opened at 0.79 on Thursday. The firm’s fifty day moving average is 0.69 and its 200 day moving average is 1.30. GRI Bio has a fifty-two week low of 0.30 and a fifty-two week high of 65.00.

Hedge Funds Weigh In On GRI Bio

An institutional investor recently bought a new position in GRI Bio stock. Armistice Capital LLC acquired a new stake in shares of GRI Bio, Inc. (NASDAQ:GRI) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 50,207 shares of the company’s stock, valued at approximately $96,000. Armistice Capital LLC owned approximately 9.23% of GRI Bio as of its most recent filing with the Securities & Exchange Commission. 33.95% of the stock is currently owned by institutional investors.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.